trending Market Intelligence /marketintelligence/en/news-insights/trending/jf-a0udu6jszahtfhdnvbg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Akebia Therapeutics prices offering to raise $89M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Akebia Therapeutics prices offering to raise $89M

Akebia Therapeutics, Inc. priced its previously announced stock offering, looking to raise $89 million via the sale of 8.5 million shares at $10.50 each.

Morgan Stanley is acting as sole book-running manager for the Cambridge, Mass.-based biotechnology company's offering, expected to close by March 27.

The offering's underwriter has an option to buy an additional 1,275,000 shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, meant to treat anemia associated with chronic kidney disease.